160 related articles for article (PubMed ID: 37013480)
1. miR-34a-5p as molecular hub of pathomechanisms in Huntington's disease.
Hart M; Diener C; Lunkes L; Rheinheimer S; Krammes L; Keller A; Meese E
Mol Med; 2023 Apr; 29(1):43. PubMed ID: 37013480
[TBL] [Abstract][Full Text] [Related]
2. Integrated Bioinformatics Analysis of Shared Genes, miRNA, Biological Pathways and Their Potential Role as Therapeutic Targets in Huntington's Disease Stages.
Christodoulou CC; Papanicolaou EZ
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902304
[TBL] [Abstract][Full Text] [Related]
3. miR-10b-5p expression in Huntington's disease brain relates to age of onset and the extent of striatal involvement.
Hoss AG; Labadorf A; Latourelle JC; Kartha VK; Hadzi TC; Gusella JF; MacDonald ME; Chen JF; Akbarian S; Weng Z; Vonsattel JP; Myers RH
BMC Med Genomics; 2015 Mar; 8():10. PubMed ID: 25889241
[TBL] [Abstract][Full Text] [Related]
4. Identification of key microRNAs associated with diffuse large B-cell lymphoma by analyzing serum microRNA expressions.
Meng Y; Quan L; Liu A
Gene; 2018 Feb; 642():205-211. PubMed ID: 29128636
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs located in the Hox gene clusters are implicated in huntington's disease pathogenesis.
Hoss AG; Kartha VK; Dong X; Latourelle JC; Dumitriu A; Hadzi TC; Macdonald ME; Gusella JF; Akbarian S; Chen JF; Weng Z; Myers RH
PLoS Genet; 2014 Feb; 10(2):e1004188. PubMed ID: 24586208
[TBL] [Abstract][Full Text] [Related]
6. Circulating microRNAs in Huntington's disease: Emerging mediators in metabolic impairment.
Díez-Planelles C; Sánchez-Lozano P; Crespo MC; Gil-Zamorano J; Ribacoba R; González N; Suárez E; Martínez-Descals A; Martínez-Camblor P; Álvarez V; Martín-Hernández R; Huerta-Ruíz I; González-García I; Cosgaya JM; Visioli F; Dávalos A; Iglesias-Gutiérrez E; Tomás-Zapico C
Pharmacol Res; 2016 Jun; 108():102-110. PubMed ID: 27155059
[TBL] [Abstract][Full Text] [Related]
7. Perturbations in the p53/miR-34a/SIRT1 pathway in the R6/2 Huntington's disease model.
Reynolds RH; Petersen MH; Willert CW; Heinrich M; Nymann N; Dall M; Treebak JT; Björkqvist M; Silahtaroglu A; Hasholt L; Nørremølle A
Mol Cell Neurosci; 2018 Apr; 88():118-129. PubMed ID: 29289683
[TBL] [Abstract][Full Text] [Related]
8. Bioinformatic analysis of a microRNA regulatory network in Huntington's disease.
Wang ZM; Dong XY; Cong SY
J Integr Neurosci; 2020 Dec; 19(4):641-650. PubMed ID: 33378838
[TBL] [Abstract][Full Text] [Related]
9. Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4
Hart M; Nickl L; Walch-Rueckheim B; Krammes L; Rheinheimer S; Diener C; Taenzer T; Kehl T; Sester M; Lenhof HP; Keller A; Meese E
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33229509
[TBL] [Abstract][Full Text] [Related]
10. MiR-34a-5p and miR-452-5p: The Novel Regulators of Pancreatic Endocrine Dysfunction in Diabetic Zucker Rats?
Su T; Hou J; Liu T; Dai P; Qin L; Ding L; Hu Y; Guo X
Int J Med Sci; 2021; 18(14):3171-3181. PubMed ID: 34400887
[No Abstract] [Full Text] [Related]
11. Altered microRNA regulation in Huntington's disease models.
Lee ST; Chu K; Im WS; Yoon HJ; Im JY; Park JE; Park KH; Jung KH; Lee SK; Kim M; Roh JK
Exp Neurol; 2011 Jan; 227(1):172-9. PubMed ID: 21035445
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatic gene analysis for potential therapeutic targets of Huntington's disease in pre-symptomatic and symptomatic stage.
Xiang C; Cong S; Liang B; Cong S
J Transl Med; 2020 Oct; 18(1):388. PubMed ID: 33054835
[TBL] [Abstract][Full Text] [Related]
13. Interrogation of brain miRNA and mRNA expression profiles reveals a molecular regulatory network that is perturbed by mutant huntingtin.
Jin J; Cheng Y; Zhang Y; Wood W; Peng Q; Hutchison E; Mattson MP; Becker KG; Duan W
J Neurochem; 2012 Nov; 123(4):477-90. PubMed ID: 22906125
[TBL] [Abstract][Full Text] [Related]
14. High-Throughput Sequencing of BACHD Mice Reveals Upregulation of Neuroprotective miRNAs at the Pre-Symptomatic Stage of Huntington's Disease.
Olmo IG; Olmo RP; Gonçalves ANA; Pires RGW; Marques JT; Ribeiro FM
ASN Neuro; 2021; 13():17590914211009857. PubMed ID: 33906482
[TBL] [Abstract][Full Text] [Related]
15. Identification of differentially expressed genes and regulatory relationships in Huntington's disease by bioinformatics analysis.
Dong X; Cong S
Mol Med Rep; 2018 Mar; 17(3):4317-4326. PubMed ID: 29328442
[TBL] [Abstract][Full Text] [Related]
16. microRNA-128a dysregulation in transgenic Huntington's disease monkeys.
Kocerha J; Xu Y; Prucha MS; Zhao D; Chan AW
Mol Brain; 2014 Jun; 7():46. PubMed ID: 24929669
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA editing patterns in Huntington's disease.
Guo S; Yang J; Jiang B; Zhou N; Ding H; Zhou G; Wu S; Suo A; Wu X; Xie W; Li W; Liu Y; Deng W; Zheng Y
Sci Rep; 2022 Feb; 12(1):3173. PubMed ID: 35210471
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p.
Li YY; Tao YW; Gao S; Li P; Zheng JM; Zhang SE; Liang J; Zhang Y
EBioMedicine; 2018 Oct; 36():209-220. PubMed ID: 30243489
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis.
Shen Y; Cheng L; Xu M; Wang W; Wan Z; Xiong H; Guo W; Cai M; Xu F
Metabolism; 2023 Sep; 146():155657. PubMed ID: 37422021
[TBL] [Abstract][Full Text] [Related]
20. In silico analysis of regulatory networks underlines the role of miR-10b-5p and its target BDNF in huntington's disease.
Müller S
Transl Neurodegener; 2014; 3():17. PubMed ID: 25210621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
